Subcutaneous immunoglobulin: opportunities and outlook

Area of Science:

• Immunology
• Pharmacology

Background:

• Subcutaneous immunoglobulin (SCIg) administration is gaining popularity due to its convenience and favorable side effect profile compared to intravenous (IV) immunoglobulin.
• A key limitation of SCIg is the large volume required, necessitating frequent, multi-site administrations.
• Current research primarily focuses on SCIg in patients previously treated with IV formulations.

Purpose of the Study:

• To review the current status and future potential of subcutaneous immunoglobulin (SCIg) administration.
• To highlight new data supporting SCIg use in previously untreated patients with primary immunodeficiencies.
• To discuss advancements facilitating SCIg administration and its potential in other conditions.

Main Methods:

• Literature review of studies on subcutaneous immunoglobulin (SCIg) administration.
• Analysis of current data regarding SCIg efficacy and patient outcomes.
• Exploration of novel developments in SCIg delivery methods.

Main Results:

• SCIg is effective in primary immunodeficiencies and offers advantages over IV immunoglobulin.
• New evidence supports SCIg use in treatment-naïve patients.
• Advancements like hyaluronidase, concentrated formulations, and rapid-push techniques are improving SCIg administration.

Conclusions:

• Subcutaneous immunoglobulin (SCIg) administration is a viable and increasingly preferred route for immunoglobulin replacement therapy.
• SCIg shows promise for autoimmune neurological conditions, though further comparative trials are needed.
• Technological innovations are expected to further enhance the adoption and utility of SCIg.